The average age was higher in the Sinopharm-based regimens (SSS and SSP, approximately 54 years) than in the Pfizer and Sputnik groups (49–52 years), reflecting the demographic pattern of the vaccine rollout in Serbia, although this difference did not reach statistical significance (one-way ANOVA, p = 0.08).
1
0.0800
0.0800